These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 33506736

  • 21. The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council.
    Nikitin D, Makam AN, Suh K, McKenna A, Carlson JJ, Richardson M, Rind DM, Pearson SD.
    J Manag Care Spec Pharm; 2023 Feb; 29(2):216-221. PubMed ID: 36705279
    [Abstract] [Full Text] [Related]

  • 22. The Effectiveness and Value of Treatments for Spinal Muscular Atrophy.
    Pearson SD, Thokala P, Stevenson M, Rind D.
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1300-1306. PubMed ID: 31778620
    [Abstract] [Full Text] [Related]

  • 23. The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis.
    Synnott PG, Bloudek LM, Sharaf R, Carlson JJ, Pearson SD.
    J Manag Care Spec Pharm; 2020 Mar; 26(3):236-239. PubMed ID: 32105176
    [Abstract] [Full Text] [Related]

  • 24. The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression.
    Agboola F, Atlas SJ, Touchette DR, Fazioli K, Pearson SD.
    J Manag Care Spec Pharm; 2020 Jan; 26(1):16-20. PubMed ID: 31880219
    [Abstract] [Full Text] [Related]

  • 25. The effectiveness and value of gene therapy for hemophilia: A Summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum.
    Tice JA, Walton SM, Sarker J, Moradi A, Chu JN, Herce-Hagiwara B, Fahim SM, Agboola F, Rind D, Pearson SD.
    J Manag Care Spec Pharm; 2023 May; 29(5):576-581. PubMed ID: 37121251
    [Abstract] [Full Text] [Related]

  • 26. Oral treatments for outpatient COVID-19: Effectiveness and value.
    Beinfeld M, Yeung K, Whittington MD, Mohammed R, Nhan E, Pearson SD.
    J Manag Care Spec Pharm; 2022 Aug; 28(8):903-909. PubMed ID: 35876296
    [Abstract] [Full Text] [Related]

  • 27. The Effectiveness and Value of Biologic Therapies for the Treatment of Uncontrolled Asthma.
    Tice JA, Campbell JD, Synnott PG, Walsh JME, Kumar VM, Whittington M, Adair E, Rind D, Pearson SD.
    J Manag Care Spec Pharm; 2019 May; 25(5):510-514. PubMed ID: 31039065
    [Abstract] [Full Text] [Related]

  • 28. The Effectiveness and Value of Patisiran and Inotersen for Hereditary Transthyretin Amyloidosis.
    Mickle K, Lasser KE, Hoch JS, Cipriano LE, Dreitlein WB, Pearson SD.
    J Manag Care Spec Pharm; 2019 Jan; 25(1):10-15. PubMed ID: 30589627
    [Abstract] [Full Text] [Related]

  • 29. Gene therapies for sickle cell disease: Effectiveness and value.
    Nikitin D, Beaudoin FL, Thokala P, McKenna A, Nhan E, Rind DM, Pearson SD.
    J Manag Care Spec Pharm; 2023 Nov; 29(11):1253-1259. PubMed ID: 37889869
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Can We Develop Sustainable and Sharable Cost-Effectiveness Models for Value Assessment in the U.S. Health Care System?
    Chapman RH, Kumar V.
    J Manag Care Spec Pharm; 2019 May; 25(5):521-524. PubMed ID: 31039064
    [Abstract] [Full Text] [Related]

  • 32. The Effectiveness and Value of Lanadelumab and C1 Esterase Inhibitors for Prophylaxis of Hereditary Angioedema Attacks.
    Agboola F, Lubinga S, Carlson J, Lin GA, Dreitlein WB, Pearson SD.
    J Manag Care Spec Pharm; 2019 Feb; 25(2):143-148. PubMed ID: 30698087
    [Abstract] [Full Text] [Related]

  • 33. A Summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council.
    Otuonye IS, Banken R, Kumar VM, Pearson SD.
    J Manag Care Spec Pharm; 2019 Jun; 25(6):630-634. PubMed ID: 31134864
    [Abstract] [Full Text] [Related]

  • 34. Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value.
    McKenna A, Lin GA, Whittington MD, Nikitin D, Herron-Smith S, Campbell JD, Agboola F, Pearson SD.
    J Manag Care Spec Pharm; 2023 Jul; 29(7):857-861. PubMed ID: 37404068
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access.
    Hong E, Zampoli M, Beringer PM.
    Clin Pharmacol Ther; 2024 Jun; 115(6):1204-1207. PubMed ID: 38385853
    [No Abstract] [Full Text] [Related]

  • 36. Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.
    Vadagam P, Kamal KM, Covvey JR, Giannetti V, Mukherjee K.
    J Manag Care Spec Pharm; 2018 Oct; 24(10):987-997. PubMed ID: 30247102
    [Abstract] [Full Text] [Related]

  • 37. The Authors Respond: Reframing the Value of Treatments for Relapsed Refractory Multiple Myeloma.
    Carlson JJ, Guzauskas GF, Chapman RH, Synnott PG, Liu S, Russo ET, Pearson SD, Brouwer ED, Ollendorf DA.
    J Manag Care Spec Pharm; 2018 Jul; 24(7):712-713. PubMed ID: 29952702
    [Abstract] [Full Text] [Related]

  • 38. New Drug Hailed as Major Breakthrough in Cystic Fibrosis.
    Am J Med Genet A; 2020 Jan; 182(1):8-9. PubMed ID: 31825178
    [No Abstract] [Full Text] [Related]

  • 39. The march towards CFTR modulator access for all people with CF: The end of the beginning.
    VanDevanter DR.
    J Cyst Fibros; 2021 Mar; 20(2):185-187. PubMed ID: 33495080
    [No Abstract] [Full Text] [Related]

  • 40. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
    Med Lett Drugs Ther; 2016 Mar 28; 58(1491):41-2. PubMed ID: 27027688
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.